256 related articles for article (PubMed ID: 18253130)
1. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors.
Lemos C; Jansen G; Peters GJ
Br J Cancer; 2008 Mar; 98(5):857-62. PubMed ID: 18253130
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.
Nakanishi T; Ross DD
Chin J Cancer; 2012 Feb; 31(2):73-99. PubMed ID: 22098950
[TBL] [Abstract][Full Text] [Related]
3. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.
Noguchi K; Katayama K; Mitsuhashi J; Sugimoto Y
Adv Drug Deliv Rev; 2009 Jan; 61(1):26-33. PubMed ID: 19111841
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer resistance protein (BCRP) in acute leukemia.
Plasschaert SL; Van Der Kolk DM; De Bont ES; Vellenga E; Kamps WA; De Vries EG
Leuk Lymphoma; 2004 Apr; 45(4):649-54. PubMed ID: 15160935
[TBL] [Abstract][Full Text] [Related]
6. Role of the breast cancer resistance protein (ABCG2) in drug transport.
Mao Q; Unadkat JD
AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.
Azzariti A; Porcelli L; Simone GM; Quatrale AE; Colabufo NA; Berardi F; Perrone R; Zucchetti M; D'Incalci M; Xu JM; Paradiso A
Cancer Chemother Pharmacol; 2010 Jan; 65(2):335-46. PubMed ID: 19495754
[TBL] [Abstract][Full Text] [Related]
8. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).
Ni Z; Bikadi Z; Rosenberg MF; Mao Q
Curr Drug Metab; 2010 Sep; 11(7):603-17. PubMed ID: 20812902
[TBL] [Abstract][Full Text] [Related]
9. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.
Natarajan K; Xie Y; Baer MR; Ross DD
Biochem Pharmacol; 2012 Apr; 83(8):1084-103. PubMed ID: 22248732
[TBL] [Abstract][Full Text] [Related]
10. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells.
Martín V; Sanchez-Sanchez AM; Herrera F; Gomez-Manzano C; Fueyo J; Alvarez-Vega MA; Antolín I; Rodriguez C
Br J Cancer; 2013 May; 108(10):2005-12. PubMed ID: 23632480
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.
Lepper ER; Nooter K; Verweij J; Acharya MR; Figg WD; Sparreboom A
Pharmacogenomics; 2005 Mar; 6(2):115-38. PubMed ID: 15882131
[TBL] [Abstract][Full Text] [Related]
12. Reversing multidrug resistance by tyrosine kinase inhibitors.
He M; Wei MJ
Chin J Cancer; 2012 Mar; 31(3):126-33. PubMed ID: 22237041
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters.
Ozvegy-Laczka C; Cserepes J; Elkind NB; Sarkadi B
Drug Resist Updat; 2005; 8(1-2):15-26. PubMed ID: 15939339
[TBL] [Abstract][Full Text] [Related]
14. Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins.
Wang XK; Fu LW
Curr Drug Metab; 2010 Sep; 11(7):618-28. PubMed ID: 20812904
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
Pérez-Tomás R
Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
[TBL] [Abstract][Full Text] [Related]
16. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T>C) of BCRP/ABCG2 gene.
Kawahara H; Noguchi K; Katayama K; Mitsuhashi J; Sugimoto Y
Cancer Sci; 2010 Jun; 101(6):1493-500. PubMed ID: 20345483
[TBL] [Abstract][Full Text] [Related]
18. Role of ABC transporters in cancer chemotherapy.
Sun YL; Patel A; Kumar P; Chen ZS
Chin J Cancer; 2012 Feb; 31(2):51-7. PubMed ID: 22257384
[TBL] [Abstract][Full Text] [Related]
19. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
20. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]